Anne Ruggiero, Individually and as Representative of the Estate of Albert Ruggiero v. Warner-Lambert Company and Parke Davis, Docket No. 04-6674-Cv

424 F.3d 249, 68 Fed. R. Serv. 304, 2005 U.S. App. LEXIS 19899
CourtCourt of Appeals for the Second Circuit
DecidedSeptember 16, 2005
Docket249
StatusPublished
Cited by177 cases

This text of 424 F.3d 249 (Anne Ruggiero, Individually and as Representative of the Estate of Albert Ruggiero v. Warner-Lambert Company and Parke Davis, Docket No. 04-6674-Cv) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Anne Ruggiero, Individually and as Representative of the Estate of Albert Ruggiero v. Warner-Lambert Company and Parke Davis, Docket No. 04-6674-Cv, 424 F.3d 249, 68 Fed. R. Serv. 304, 2005 U.S. App. LEXIS 19899 (2d Cir. 2005).

Opinion

DENNIS JACOBS, Circuit Judge.

Plaintiff Anne Ruggiero appeals from a judgment entered by the United States District Court for the Southern District of New York (Kaplan, /.), dismissing on summary judgment a complaint alleging that her husband’s cirrhosis and death were caused by Rezulin, a diabetes medication manufactured and sold by defendants Warner-Lambert Co. and Parke Davis (“Defendants”). The ground for dismissal was that Ruggiero failed to produce sufficient evidence that Rezulin was capable of causing or exacerbating cirrhosis (so-called “general” causation). On appeal, Ruggiero argues principally that [i] the ruling on general causation was error because that issue was first raised in Defendants’ summary-judgment reply papers, and is a subject of on-going consolidated proceedings in the multi-district litigation (“MDL”) of which Ruggiero’s case is part; and [ii] medical expert evidence attributing Mr. Ruggiero’s cirrhosis and death to Rezulin was erroneously ruled inadmissible. For the following reasons, we affirm.

BACKGROUND

Albert Ruggiero was diagnosed with Type-II diabetes in 1982, and in May 1997, he began taking Rezulin, a diabetes medication manufactured and sold by Defendants. His death on August 24, 1998 was attributed to liver failure caused by cirrhosis. On March 21, 2000, Defendants halted distribution of Rezulin at the request of the Food and Drug Administration, in light of concerns that the drug caused increased liver toxicity.

Anne Ruggiero commenced this product-liability action, claiming that Rezulin caused Albert’s cirrhosis. The case was added to the “[m]ore than one thousand” Rezulin-related cases consolidated for pretrial proceedings in the Southern District of New York, before Judge Kaplan. In re Rezulin Prods. Liab. Litig. (MDL No. 1848), 223 F.R.D. 109, 111 (S.D.N.Y.2004). Defendants subsequently moved for summary judgment in Ruggiero’s individual case.

The district court granted summary judgment, holding that Ruggiero produced insufficient evidence of “general” causation, i.e., evidence that Rezulin is capable of causing or exacerbating cirrhosis of the liver. 1 Specifically, the court ruled that the sole evidence of general causation submitted by Ruggiero — the expert opinion of Dr. Douglas T. Dietrich — was inadmissible (as to that issue) under Fed R. Evid. 702 (“Testimony by Experts”) and Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). The court reasoned that “Dr. Dietrich was unable to point to any studies or, for that matter, anything else that suggested that cirrhosis could be caused or exacerbated by Rezulin.” Dr. Dietrich’s opinion rested on a review of Albert’s medical records and a “differential diagnosis,” i e., a patient-specific process of ruling out potential causes of an illness as unlikely, until one cause remains. 2 The court con- *252 eluded that this approach did not provide a reliable basis for Dr. Dietrich’s opinion that Rezulin is capable of causing or exacerbating cirrhosis.

DISCUSSION

We review the grant of summary judgment de novo. See Anthony v. City of New York, 339 F.3d 129, 134 (2d Cir.2003). A ruling as to the admissibility of expert evidence is reviewed for abuse of discretion. See Gen. Elec. Co. v. Joiner, 522 U.S. 136, 142-43, 118 S.Ct. 512, 139 L.Ed.2d 508 (1997) (“On a motion for summary judgment .... the question of admissibility of expert testimony ... is reviewable under the abuse-of-discretion standard.”).

I

As a threshold matter, Ruggiero claims that the district court should not have reached the issue of general causation.

First, she argues that the issue was first raised in Defendants’ summary-judgment reply papers. See, e.g., Playboy Enters., Inc. v. Dumas, 960 F.Supp. 710, 720 n. 7 (S.D.N.Y.1997) (“Arguments made for the first time in a reply brief need not be considered by a court.”). Assuming that is so, the district court had discretion to consider it. See Bayway Ref. v. Oxygenated Mktg. & Trading, 215 F.3d 219, 226 (2d Cir.2000) (reviewing for abuse of discretion district court’s decision to rely on evidence submitted with moving party’s reply papers).

Defendants’ moving papers did not argue expressly in terms of general causation. However [i] the motion was cast in terms of the broader and subsuming argument that Ruggiero could not “establish the essential element of causation”; [ii] a declaration appended to the moving papers noted that “[tjhere are no scientific studies in the medical literature that conclude Rezulin can cause cirrhosis”; and [iii] Ruggiero’s opposition papers cited as a genuine issue of material fact “[wjhether or not there are scientific studies in the medical literature that conclude Rezulin can cause liver failure such as caused decedent Albert Ruggiero’s death.” Under the circumstances, Ruggiero cannot claim that she was blindsided by Defendants’ reliance on general causation or that she was prejudiced by the district court’s consideration of that issue. 3 In any event, it is hard for Ruggiero to claim unfair prejudice now, because she could have claimed surprise in the district court and sought to file a responsive sur-reply. 4

*253 Second, Ruggiero argues that the district court should not have considered the issue of general causation because that issue [i] is being litigated by the “Plaintiffs Executive Committee” in the consolidated MDL proceedings and [ii] implicates the law-of-the-case doctrine by reason of a previous contrary decision in those consolidated proceedings (or somewhere else). Even assuming that the law-of-the-case doctrine would apply, Ruggiero’s brief directs us to no such contrary ruling.

In any event, we decline to consider the merits of this argument because Ruggiero failed to present it to the district court. Id. We have discretion to consider issues that a party failed to raise in the district court, see Booking v. Gen. Star Mgmt. Co., 254 F.3d 414, 418-19 (2d Cir.2001), but we decline to do so here. For the reasons stated above, there is no good excuse for Ruggiero’s failure to bring this complaint to the district court’s attention; and we are most hesitant to consider it in the first instance, given the unmatched expertise Judge Kaplan has acquired while presiding over the Rezulin MDL over the past five years.

II

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
424 F.3d 249, 68 Fed. R. Serv. 304, 2005 U.S. App. LEXIS 19899, Counsel Stack Legal Research, https://law.counselstack.com/opinion/anne-ruggiero-individually-and-as-representative-of-the-estate-of-albert-ca2-2005.